{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T14:51:14Z","timestamp":1785336674262,"version":"3.55.0"},"reference-count":72,"publisher":"American Association for Cancer Research (AACR)","issue":"10","license":[{"start":{"date-parts":[[2022,10,3]],"date-time":"2022-10-03T00:00:00Z","timestamp":1664755200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"HHS | NIH | National Cancer Institute","award":["R01CA207751"],"award-info":[{"award-number":["R01CA207751"]}]},{"name":"HHS | NIH | National Cancer Institute","award":["R01CA232589"],"award-info":[{"award-number":["R01CA232589"]}]},{"name":"HHS | NIH | National Cancer Institute","award":["P30CA023168"],"award-info":[{"award-number":["P30CA023168"]}]},{"name":"Indiana Clinical and Translational Science Institute","award":["UL1TR002529"],"award-info":[{"award-number":["UL1TR002529"]}]},{"name":"HHS | NIH | National Cancer Institute","award":["F99CA264734"],"award-info":[{"award-number":["F99CA264734"]}]},{"DOI":"10.13039\/100000048","name":"American Cancer Society","doi-asserted-by":"crossref","award":["RSG-CSM130259"],"award-info":[{"award-number":["RSG-CSM130259"]}],"id":[{"id":"10.13039\/100000048","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,10,3]]},"abstract":"<jats:p>SH2 containing protein tyrosine phosphatase-2 (SHP2) is recognized as a druggable oncogenic phosphatase that is expressed in both tumor cells and immune cells. How tumor cell\u2013autonomous SHP2 contributes to an immunosuppressive tumor microenvironment (TME) and therapeutic failure of immune checkpoint blockades in metastatic breast cancer (MBC) is not fully understood. Herein, we utilized systemic SHP2 inhibition and inducible genetic depletion of SHP2 to investigate immune reprogramming during SHP2 targeting. Pharmacologic inhibition of SHP2 sensitized MBC cells growing in the lung to \u03b1-programmed death ligand 1 (\u03b1-PD-L1) antibody treatment via relieving T-cell exhaustion induced by checkpoint blockade. Tumor cell\u2013specific depletion of SHP2 similarly reduced pulmonary metastasis and also relieved exhaustion markers on CD8+ and CD4+ cells. Both systemic SHP2 inhibition and tumor cell\u2013autonomous SHP2 depletion reduced tumor-infiltrated CD4+ T cells and M2-polarized tumor-associated macrophages. Analysis of TCGA datasets revealed that phosphorylation of SHP2 is important for immune-cell infiltration, T-cell activation and antigen presentation. To investigate this mechanistically, we conducted in vitro T-cell killing assays, which demonstrated that pretreatment of tumor cells with FGF2 and PDGF reduced the cytotoxicity of CD8+ T cells in a SHP2-dependent manner. Both growth factor receptor signaling and three-dimensional culture conditions transcriptionally induced PD-L1 via SHP2. Finally, SHP2 inhibition reduced MAPK signaling and enhanced STAT1 signaling, preventing growth factor\u2013mediated suppression of MHC class I. Overall, our findings support the conclusion that tumor cell\u2013autonomous SHP2 is a key signaling node utilized by MBC cells to engage immune-suppressive mechanisms in response to diverse signaling inputs from TME.<\/jats:p>\n                  <jats:sec>\n                    <jats:title>Significance:<\/jats:title>\n                    <jats:p>Findings present inhibition of SHP2 as a therapeutic option to limit breast cancer metastasis by promoting antitumor immunity.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1158\/2767-9764.crc-22-0117","type":"journal-article","created":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T10:01:30Z","timestamp":1662026490000},"page":"1104-1118","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Tumor Cell\u2013Autonomous SHP2 Contributes to Immune Suppression in Metastatic Breast Cancer"],"prefix":"10.1158","volume":"2","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2070-5062","authenticated-orcid":true,"given":"Hao","family":"Chen","sequence":"first","affiliation":[{"name":"1Department of Medicinal Chemistry and Molecular Pharmacology, Purdue University, West Lafayette, Indiana."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0616-0366","authenticated-orcid":true,"given":"Gregory M.","family":"Cresswell","sequence":"additional","affiliation":[{"name":"2Department of Comparative Pathobiology, Purdue University, West Lafayette, Indiana."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8336-5862","authenticated-orcid":true,"given":"Sarah","family":"Libring","sequence":"additional","affiliation":[{"name":"3Department of Biomedical Engineering, Purdue University, West Lafayette, Indiana."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4049-9013","authenticated-orcid":true,"given":"Mitchell G.","family":"Ayers","sequence":"additional","affiliation":[{"name":"1Department of Medicinal Chemistry and Molecular Pharmacology, Purdue University, West Lafayette, Indiana."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinmin","family":"Miao","sequence":"additional","affiliation":[{"name":"1Department of Medicinal Chemistry and Molecular Pharmacology, Purdue University, West Lafayette, Indiana."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhong-Yin","family":"Zhang","sequence":"additional","affiliation":[{"name":"1Department of Medicinal Chemistry and Molecular Pharmacology, Purdue University, West Lafayette, Indiana."},{"name":"4Purdue University Center for Cancer Research, Purdue University, West Lafayette, Indiana."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis","family":"Solorio","sequence":"additional","affiliation":[{"name":"3Department of Biomedical Engineering, Purdue University, West Lafayette, Indiana."},{"name":"4Purdue University Center for Cancer Research, Purdue University, West Lafayette, Indiana."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4221-5416","authenticated-orcid":true,"given":"Timothy L.","family":"Ratliff","sequence":"additional","affiliation":[{"name":"2Department of Comparative Pathobiology, Purdue University, West Lafayette, Indiana."},{"name":"4Purdue University Center for Cancer Research, Purdue University, West Lafayette, Indiana."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3665-7413","authenticated-orcid":true,"given":"Michael K.","family":"Wendt","sequence":"additional","affiliation":[{"name":"1Department of Medicinal Chemistry and Molecular Pharmacology, Purdue University, West Lafayette, Indiana."},{"name":"4Purdue University Center for Cancer Research, Purdue University, West Lafayette, Indiana."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1086","published-online":{"date-parts":[[2022,10,3]]},"reference":[{"key":"2023032313395031700_","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3322\/caac.21654","article-title":"Cancer statistics, 2021","volume":"71","author":"Siegel","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"2023032313395031700_","first-page":"23","article-title":"Comparison of treatment costs for breast cancer, by tumor stage and type of service","volume":"9","author":"Blumen","year":"2016","journal-title":"Am Health Drug Benefits"},{"key":"2023032313395031700_","doi-asserted-by":"crossref","first-page":"pkab063","DOI":"10.1093\/jncics\/pkab063","article-title":"Projecting the prevalence and costs of metastatic breast cancer from 2015 through 2030","volume":"5","author":"Gogate","year":"2021","journal-title":"JNCI Cancer Spectr"},{"key":"2023032313395031700_","doi-asserted-by":"crossref","first-page":"e175","DOI":"10.1016\/S1470-2045(19)30026-9","article-title":"Immunotherapy and targeted therapy combinations in metastatic breast cancer","volume":"20","author":"Esteva","year":"2019","journal-title":"Lancet Oncol"},{"key":"2023032313395031700_","first-page":"112","article-title":"Trends in the global immuno-oncology landscape","volume":"130","author":"Tang","year":"2018","journal-title":"Nat Rev Drug Discov"},{"key":"2023032313395031700_","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1093\/annonc\/mdy518","article-title":"Pembrolizumab monotherapy for previously untreated, PD-L1-positive, metastatic triple-negative breast cancer: cohort B of the phase II KEYNOTE-086 study","volume":"30","author":"Adams","year":"2019","journal-title":"Ann Oncol"},{"key":"2023032313395031700_","volume-title":"Phase 2 Study of Pembrolizumab as First-line Therapy for PD-L1\u2013positive Metastatic Triple-negative Breast Cancer (mTNBC): Preliminary Data From KEYNOTE-086 Cohort B","author":"Adams","year":"2017"},{"key":"2023032313395031700_","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1056\/NEJMoa1910549","article-title":"Pembrolizumab for early triple-negative breast cancer","volume":"382","author":"Schmid","year":"2020","journal-title":"N Engl J Med"},{"key":"2023032313395031700_","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/s10549-021-06405-2","article-title":"Novel classes of immunotherapy for breast cancer","volume":"191","author":"Hernando-Calvo","year":"2022","journal-title":"Breast Cancer Res Treat"},{"key":"2023032313395031700_","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41467-018-06823-9","article-title":"Structural reorganization of SHP2 by oncogenic mutations and implications for oncoprotein resistance to allosteric inhibition","volume":"9","author":"LaRochelle","year":"2018","journal-title":"Nat Commun"},{"key":"2023032313395031700_","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.canlet.2019.11.009","article-title":"Immune cells within the tumor microenvironment: Biological functions and roles in cancer immunotherapy","volume":"470","author":"Lei","year":"2020","journal-title":"Cancer Lett"},{"key":"2023032313395031700_","doi-asserted-by":"crossref","first-page":"2075","DOI":"10.1111\/jcmm.12618","article-title":"Functions of Shp2 in cancer","volume":"19","author":"Zhang","year":"2015","journal-title":"J Cell Mol Med"},{"key":"2023032313395031700_","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.it.2006.01.007","article-title":"SHP2 forecast for the immune system: fog gradually clearing","volume":"27","author":"Salmond","year":"2006","journal-title":"Trends Immunol"},{"key":"2023032313395031700_","doi-asserted-by":"crossref","first-page":"104595","DOI":"10.1016\/j.phrs.2019.104595","article-title":"Targeting SHP2 as a promising strategy for cancer immunotherapy","volume":"152","author":"Liu","year":"2020","journal-title":"Pharmacol Res"},{"key":"2023032313395031700_","doi-asserted-by":"crossref","first-page":"7875","DOI":"10.1128\/MCB.23.21.7875-7886.2003","article-title":"Molecular mechanism for a role of SHP2 in epidermal growth factor receptor signaling","volume":"23","author":"Agazie","year":"2003","journal-title":"Mol Cell Biol"},{"key":"2023032313395031700_","doi-asserted-by":"crossref","first-page":"8859","DOI":"10.1038\/ncomms9859","article-title":"Inhibition of SHP2-mediated dephosphorylation of Ras suppresses oncogenesis","volume":"6","author":"Bunda","year":"2015","journal-title":"Nat Commun"},{"key":"2023032313395031700_","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1038\/s41591-018-0024-8","article-title":"Mutant KRAS-driven cancers depend on PTPN11\/SHP2 phosphatase","volume":"24","author":"Ruess","year":"2018","journal-title":"Nat Med"},{"key":"2023032313395031700_","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1038\/leu.2016.326","article-title":"Inhibition of the Gab2\/PI3K\/mTOR signaling ameliorates myeloid malignancy caused by Ptpn11 (Shp2) gain-of-function mutations","volume":"31","author":"Liu","year":"2017","journal-title":"Leukemia"},{"key":"2023032313395031700_","doi-asserted-by":"crossref","first-page":"7166","DOI":"10.1038\/s41388-020-01488-5","article-title":"SHP2 is a multifunctional therapeutic target in drug resistant metastatic breast cancer","volume":"39","author":"Chen","year":"2020","journal-title":"Oncogene"},{"key":"2023032313395031700_","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13058-015-0659-z","article-title":"SHP2 acts both upstream and downstream of multiple receptor tyrosine kinases to promote basal-like and triple-negative breast cancer","volume":"18","author":"Matalkah","year":"2016","journal-title":"Breast Cancer Res"},{"key":"2023032313395031700_","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1084\/jem.20112741","article-title":"Programmed cell death 1 forms negative costimulatory microclusters that directly inhibit T cell receptor signaling by recruiting phosphatase SHP2","volume":"209","author":"Yokosuka","year":"2012","journal-title":"J Exp Med"},{"key":"2023032313395031700_","doi-asserted-by":"crossref","first-page":"eaay4458","DOI":"10.1126\/sciadv.aay4458","article-title":"Molecular mechanism of SHP2 activation by PD-1 stimulation","volume":"6","author":"Marasco","year":"2020","journal-title":"Sci Adv"},{"key":"2023032313395031700_","first-page":"128","article-title":"Interaction of SHP-2 SH2 domains with PD-1 ITSM induces PD-1 dimerization and SHP-2 activation","volume":"3","author":"Patsoukis","year":"2020","journal-title":"Communications"},{"key":"2023032313395031700_","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1126\/science.aaf1292","article-title":"T cell costimulatory receptor CD28 is a primary target for PD-1\u2013mediated inhibition","volume":"355","author":"Hui","year":"2017","journal-title":"Science"},{"key":"2023032313395031700_","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.celrep.2018.03.026","article-title":"Shp-2 is dispensable for establishing T cell exhaustion and for PD-1 signaling in vivo","volume":"23","author":"Rota","year":"2018","journal-title":"Cell Rep"},{"key":"2023032313395031700_","doi-asserted-by":"crossref","first-page":"5088","DOI":"10.1038\/s41388-018-0337-6","article-title":"Myeloid-restricted ablation of Shp2 restrains melanoma growth by amplifying the reciprocal promotion of CXCL9 and IFN-\u03b3 production in tumor microenvironment","volume":"37","author":"Xiao","year":"2018","journal-title":"Oncogene"},{"key":"2023032313395031700_","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/S0092-8674(00)80938-1","article-title":"Crystal structure of the tyrosine phosphatase SHP-2","volume":"92","author":"Hof","year":"1998","journal-title":"Cell"},{"key":"2023032313395031700_","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41598-020-75409-7","article-title":"An allosteric interaction controls the activation mechanism of SHP2 tyrosine phosphatase","volume":"10","author":"Anselmi","year":"2020","journal-title":"Sci Rep"},{"key":"2023032313395031700_","doi-asserted-by":"crossref","first-page":"7773","DOI":"10.1021\/acs.jmedchem.6b00680","article-title":"Allosteric inhibition of SHP2: identification of a potent, selective, and orally efficacious phosphatase inhibitor","volume":"59","author":"Fortanet","year":"2016","journal-title":"J Med Chem"},{"key":"2023032313395031700_","doi-asserted-by":"crossref","first-page":"13578","DOI":"10.1021\/acs.jmedchem.0c01170","article-title":"Identification of TNO155, an Allosteric SHP2 Inhibitor for the Treatment of Cancer","volume":"63","author":"LaMarche","year":"2020","journal-title":"J Med Chem"},{"key":"2023032313395031700_","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1038\/nature18621","article-title":"Allosteric inhibition of SHP2 phosphatase inhibits cancers driven by receptor tyrosine kinases","volume":"535","author":"Chen","year":"2016","journal-title":"Nature"},{"key":"2023032313395031700_","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1158\/1078-0432.CCR-20-2718","article-title":"Combinations with allosteric SHP2 inhibitor TNO155 to block receptor tyrosine kinase signaling","volume":"27","author":"Liu","year":"2021","journal-title":"Clin Cancer Res"},{"key":"2023032313395031700_","doi-asserted-by":"crossref","first-page":"73817","DOI":"10.18632\/oncotarget.12074","article-title":"SHP2 phosphatase as a novel therapeutic target for melanoma treatment","volume":"7","author":"Zhang","year":"2016","journal-title":"Oncotarget"},{"key":"2023032313395031700_","first-page":"3005","article-title":"Initial results from a dose finding study of TNO155, a SHP2 inhibitor, in adults with advanced solid tumors","author":"Brana","year":"2021"},{"key":"2023032313395031700_","doi-asserted-by":"crossref","first-page":"2096","DOI":"10.1158\/1535-7163.MCT-16-0136","article-title":"Covalent targeting of fibroblast growth factor receptor inhibits metastatic breast cancer","volume":"15","author":"Brown","year":"2016","journal-title":"Mol Cancer Ther"},{"key":"2023032313395031700_","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/bcr2360","article-title":"Therapeutic targeting of the focal adhesion complex prevents oncogenic TGF-\u03b2 signaling and metastasis","volume":"11","author":"Wendt","year":"2009","journal-title":"Breast Cancer Res"},{"key":"2023032313395031700_","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/ncomms3612","article-title":"Inferring tumour purity and stromal and immune cell admixture from expression data","volume":"4","author":"Yoshihara","year":"2013","journal-title":"Nat Commun"},{"key":"2023032313395031700_","first-page":"223","article-title":"Immunedeconv: an R package for unified access to computational methods for estimating immune cell fractions from bulk RNA-sequencing data","author":"Sturm","year":"2020"},{"key":"2023032313395031700_","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1038\/s41587-019-0114-2","article-title":"Determining cell type abundance and expression from bulk tissues with digital cytometry","volume":"37","author":"Newman","year":"2019","journal-title":"Nat Biotechnol"},{"key":"2023032313395031700_","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1038\/nmeth.3337","article-title":"Robust enumeration of cell subsets from tissue expression profiles","volume":"12","author":"Newman","year":"2015","journal-title":"Nat Methods"},{"key":"2023032313395031700_","doi-asserted-by":"crossref","first-page":"15545","DOI":"10.1073\/pnas.0506580102","article-title":"Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles","volume":"102","author":"Subramanian","year":"2005","journal-title":"Proc Natl Acad Sci"},{"key":"2023032313395031700_","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1038\/ng1180","article-title":"PGC-1\u03b1-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes","volume":"34","author":"Mootha","year":"2003","journal-title":"Nat Genet"},{"key":"2023032313395031700_","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1158\/2326-6066.CIR-20-0235","article-title":"Pharmacological inhibition of FGFR modulates the metastatic immune microenvironment and promotes response to immune checkpoint blockade","volume":"8","author":"Akhand","year":"2020","journal-title":"Cancer Immunol Res"},{"key":"2023032313395031700_","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1038\/s41388-020-01530-6","article-title":"Epigenetic targeting of neuropilin-1 prevents bypass signaling in drug-resistant breast cancer","volume":"40","author":"Abdullah","year":"2021","journal-title":"Oncogene"},{"key":"2023032313395031700_","first-page":"Unit 20.2","article-title":"Mouse 4T1 breast tumor model","volume":"20","author":"Pulaski","year":"2001","journal-title":"Curr Protoc Immunol"},{"key":"2023032313395031700_","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1038\/nm.2645","article-title":"Tyrosine phosphatase SHP2 promotes breast cancer progression and maintains tumor-initiating cells via activation of key transcription factors and a positive feedback signaling loop","volume":"18","author":"Aceto","year":"2012","journal-title":"Nat Med"},{"key":"2023032313395031700_","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1158\/1541-7786.MCR-18-0151","article-title":"Autocrine fibronectin inhibits breast cancer metastasis","volume":"16","author":"Shinde","year":"2018","journal-title":"Mol Cancer Res"},{"key":"2023032313395031700_","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/S0952-7915(99)80014-4","article-title":"Antigen presentation by MHC class I and its regulation by interferon \u03b3","volume":"11","author":"Fr\u00fch","year":"1999","journal-title":"Curr Opin Immunol"},{"key":"2023032313395031700_","doi-asserted-by":"crossref","first-page":"6118","DOI":"10.1158\/1078-0432.CCR-11-0482","article-title":"The two faces of interferon-\u03b3 in cancer","volume":"17","author":"Zaidi","year":"2011","journal-title":"Clin Cancer Res"},{"key":"2023032313395031700_","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1016\/j.apsb.2018.08.009","article-title":"SHP2 inhibition triggers anti-tumor immunity and synergizes with PD-1 blockade","volume":"9","author":"Zhao","year":"2019","journal-title":"Acta Pharmaceutica Sinica B"},{"key":"2023032313395031700_","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1158\/2326-6066.CIR-19-0744","article-title":"SHP-2 and PD-L1 inhibition combined with radiotherapy enhances systemic antitumor effects in an anti-PD-1-resistant model of non-small-cell lung cancer","volume":"8","author":"Chen","year":"2020","journal-title":"Cancer Immunol Res"},{"key":"2023032313395031700_","doi-asserted-by":"crossref","first-page":"e20201414","DOI":"10.1084\/jem.20201414","article-title":"SHP2 inhibition diminishes KRASG12C cycling and promotes tumor microenvironment remodeling","volume":"218","author":"Fedele","year":"2021","journal-title":"J Exp Med"},{"key":"2023032313395031700_","first-page":"1","article-title":"SHP2 blockade enhances anti-tumor immunity via tumor cell intrinsic and extrinsic mechanisms","volume":"11","author":"Wang","year":"2021","journal-title":"Sci Rep"},{"key":"2023032313395031700_","doi-asserted-by":"crossref","first-page":"2889","DOI":"10.1158\/0008-5472.CAN-19-3038","article-title":"Allosteric inhibition of SHP2 stimulates antitumor immunity by transforming the immunosuppressive environment","volume":"80","author":"Quintana","year":"2020","journal-title":"Cancer Res"},{"key":"2023032313395031700_","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.apsb.2021.08.006","article-title":"Allosteric inhibition reveals SHP2-mediated tumor immunosuppression in colon cancer by single-cell transcriptomics","volume":"12","author":"Gao","year":"2022","journal-title":"Acta Pharmaceutica Sinica B"},{"key":"2023032313395031700_","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/j.ccell.2020.09.001","article-title":"The PD-1\/PD-L1-checkpoint restrains T cell immunity in tumor-draining lymph nodes","volume":"38","author":"Dammeijer","year":"2020","journal-title":"Cancer Cell"},{"key":"2023032313395031700_","doi-asserted-by":"crossref","first-page":"679130","DOI":"10.3389\/fmolb.2021.679130","article-title":"Deep Sequencing of T-cell receptors for monitoring peripheral CD8+ T cells in chinese advanced non\u2013small-cell lung cancer patients treated with the Anti\u2013PD-L1 antibody","volume":"8","author":"Sheng","year":"2021","journal-title":"Front Mol Biosci"},{"key":"2023032313395031700_","doi-asserted-by":"crossref","first-page":"15016","DOI":"10.1073\/pnas.0801497105","article-title":"Selective expansion of a subset of exhausted CD8 T cells by \u03b1PD-L1 blockade","volume":"105","author":"Blackburn","year":"2008","journal-title":"Proc Natl Acad Sci"},{"key":"2023032313395031700_","doi-asserted-by":"crossref","first-page":"3333","DOI":"10.1158\/1078-0432.CCR-19-3548","article-title":"FS118, a bispecific antibody targeting LAG-3 and PD-L1, enhances T-cell activation resulting in potent antitumor activity","volume":"26","author":"Kraman","year":"2020","journal-title":"Clin Cancer Res"},{"key":"2023032313395031700_","doi-asserted-by":"crossref","first-page":"149","DOI":"10.3390\/vaccines7040149","article-title":"Breast cancer cells and PD-1\/PD-L1 blockade upregulate the expression of PD-1, CTLA-4, TIM-3 and LAG-3 immune checkpoints in CD4+ T cells","volume":"7","author":"Saleh","year":"2019","journal-title":"Vaccines"},{"key":"2023032313395031700_","doi-asserted-by":"crossref","first-page":"5368","DOI":"10.1158\/1078-0432.CCR-18-1038","article-title":"Resistance to radiotherapy and PD-L1 blockade is mediated by TIM-3 upregulation and regulatory T-cell infiltration","volume":"24","author":"Oweida","year":"2018","journal-title":"Clin Cancer Res"},{"key":"2023032313395031700_","doi-asserted-by":"crossref","first-page":"2168","DOI":"10.1158\/1078-0432.CCR-20-4405","article-title":"Blocking TIM-3 in treatment-refractory advanced solid tumors: a Phase Ia\/b study of LY3321367 with or without an anti-PD-L1 antibody","volume":"27","author":"Harding","year":"2021","journal-title":"Clin Cancer Res"},{"key":"2023032313395031700_","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.ccell.2016.02.004","article-title":"Facilitating T cell infiltration in tumor microenvironment overcomes resistance to PD-L1 blockade","volume":"29","author":"Tang","year":"2016","journal-title":"Cancer Cell"},{"key":"2023032313395031700_","doi-asserted-by":"crossref","first-page":"e120631","DOI":"10.1172\/jci.insight.120631","article-title":"Compensation between CSF1R+ macrophages and Foxp3+ Treg cells drives resistance to tumor immunotherapy","author":"Gyori","year":"2018","journal-title":"JCI Insight"},{"key":"2023032313395031700_","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1158\/2326-6066.CIR-18-0272","article-title":"Intracellular activation of complement C3 leads to PD-L1 antibody treatment resistance by modulating tumor-associated macrophages","volume":"7","author":"Zha","year":"2019","journal-title":"Cancer Immunol Res"},{"key":"2023032313395031700_","doi-asserted-by":"crossref","first-page":"1904364","DOI":"10.1002\/adma.201904364","article-title":"CSF1R-and SHP2-inhibitor-loaded nanoparticles enhance cytotoxic activity and phagocytosis in tumor-associated macrophages","volume":"31","author":"Ramesh","year":"2019","journal-title":"Adv Mater"},{"key":"2023032313395031700_","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41467-021-26697-8","article-title":"Endothelial deletion of SHP2 suppresses tumor angiogenesis and promotes vascular normalization","volume":"12","author":"Xu","year":"2021","journal-title":"Nat Commun"},{"key":"2023032313395031700_","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1038\/s41591-018-0023-9","article-title":"SHP2 is required for growth of KRAS-mutant non-small-cell lung cancer in vivo","volume":"24","author":"Mainardi","year":"2018","journal-title":"Nat Med"},{"key":"2023032313395031700_","doi-asserted-by":"crossref","first-page":"2801","DOI":"10.4049\/jimmunol.1303463","article-title":"Myeloid-specific disruption of tyrosine phosphatase Shp2 promotes alternative activation of macrophages and predisposes mice to pulmonary fibrosis","volume":"193","author":"Tao","year":"2014","journal-title":"J Immunol"},{"key":"2023032313395031700_","doi-asserted-by":"crossref","first-page":"1978","DOI":"10.1016\/j.celrep.2015.08.037","article-title":"PTPN11 is a central node in intrinsic and acquired resistance to targeted cancer drugs","volume":"12","author":"Prahallad","year":"2015","journal-title":"Cell Rep"},{"key":"2023032313395031700_","doi-asserted-by":"crossref","first-page":"4309","DOI":"10.3390\/cancers13174309","article-title":"SHP2 as a potential therapeutic target in diffuse-type gastric carcinoma addicted to receptor tyrosine kinase signaling","volume":"13","author":"Nagamura","year":"2021","journal-title":"Cancers"},{"key":"2023032313395031700_","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41419-018-1034-7","article-title":"Biased signaling downstream of epidermal growth factor receptor regulates proliferative versus apoptotic response to ligand","volume":"9","author":"Ali","year":"2018","journal-title":"Cell Death Dis"}],"container-title":["Cancer Research Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article-pdf\/doi\/10.1158\/2767-9764.CRC-22-0117\/3204474\/crc-22-0117.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article-pdf\/2\/10\/1104\/3284865\/crc-22-0117.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article-pdf\/2\/10\/1104\/3284865\/crc-22-0117.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,26]],"date-time":"2023-11-26T08:26:08Z","timestamp":1700987168000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article\/2\/10\/1104\/709548\/Tumor-Cell-Autonomous-SHP2-Contributes-to-Immune"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,3]]},"references-count":72,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2022,10,3]]}},"URL":"https:\/\/doi.org\/10.1158\/2767-9764.crc-22-0117","relation":{"has-preprint":[{"id-type":"doi","id":"10.1158\/2767-9764.22545153","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.22545123","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.22545150.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.22545111","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.22545141","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.22545129","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.22545117","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.22545144.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.22545147","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.22545135","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.22545141.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.22545159","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.22545147.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.22545129.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.22545138.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.22545132.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.22545135.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.22545132","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.22545120","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.22545156","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.22545144","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.22545123.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.22545150","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.22545114.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.22545117.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.c.6550857","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.22545162","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.22545126.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.22545114","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.22545120.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.22545138","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.22545126","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.c.6550857.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.22545111.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.22545162.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.22545153.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.22545156.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.22545159.v1","asserted-by":"object"}]},"ISSN":["2767-9764"],"issn-type":[{"value":"2767-9764","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10,3]]}}}